Vaarala - Publications and supervised doctoral dissertations

Selected publications:

  1. Vaarala MH, Hirvikoski P, Kauppila S, Paavonen TK. Identification of androgen-regulated genes in human prostate. Mol Med Rep. 2012 Sep;6(3):466-72. doi: 10.3892/mmr.2012.956. Epub 2012 Jun 19. PubMed PMID: 22735730; PubMed Central PMCID: PMC3493087.
  2. Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS, Vaarala MH. Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res. 2011 Sep 19;30:84. doi: 10.1186/1756-9966-30-84. PubMed PMID: 21929816; PubMed Central PMCID: PMC3182949.
  3. Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW, Selander KS. Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat. 2012 Apr;132(2):411-9. doi: 10.1007/s10549-011-1590-3. Epub 2011 May 24. PubMed PMID: 21607583.
  4. Soini Y, Haapasaari KM, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P. 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. Int J Clin Exp Pathol. 2011 Mar;4(3):267-75. Epub 2011 Mar 2. PubMed PMID: 21487522; PubMed Central PMCID: PMC3071659.
  5. Ronkainen H, Vaarala MH, Hirvikoski P, Ristimäki A. HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol. 2011 Jun;32(3):481-7. doi: 10.1007/s13277-010-0141-6. Epub 2010 Dec 16. PubMed PMID: 21161467.
  6. Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010 Oct 21;29:136. doi: 10.1186/1756-9966-29-136. PubMed PMID: 20964854; PubMed Central PMCID: PMC2984408.
  7. Ronkainen H, Kauppila S, Hirvikoski P, Vaarala MH. Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma. J Exp Clin Cancer Res. 2010 Jan 14;29:2. doi: 10.1186/1756-9966-29-2. PubMed PMID: 20074327; PubMed Central PMCID: PMC2837630.
  8. Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, Vaarala MH. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 2010 Jun 1;70(8):817-24. doi: 10.1002/pros.21115. PubMed PMID: 20054821.
  9. Loikkanen I, Toljamo K, Hirvikoski P, Väisänen T, Paavonen TK, Vaarala MH. Myosin VI is a modulator of androgen-dependent gene expression. Oncol Rep. 2009 Nov;22(5):991-5. PubMed PMID: 19787211.
  10. Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, Hirvikoski P. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma. Oncol Rep. 2009 Jun;21(6):1519-23. PubMed PMID: 19424632.
  11. Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer. 2008 Jun 1;122(11):2511-6. doi: 10.1002/ijc.23425. PubMed PMID: 18306354.
  12. Renko O, Savolainen ER, Loikkanen I, Paavonen TK, Vaarala MH. The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia. DNA Cell Biol. 2008 Feb;27(2):109-13. PubMed PMID: 17979523.
  13. Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, Vuoristo JT, Edwards RJ, Paavonen TK. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis. 2007 May;28(5):916-21. Epub 2006 Nov 20. PubMed PMID: 17116727.
  14. Vaarala MH, Porvari K, Kyllönen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 2001 Dec 1;94(5):705-10. PubMed PMID: 11745466.
  15. Vaarala MH, Porvari KS, Kellokumpu S, Kyllönen AP, Vihko PT. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol. 2001 Jan;193(1):134-40. PubMed PMID: 11169526.
  16. Vaarala MH, Porvari K, Kyllönen A, Vihko P. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest. 2000 Aug;80(8):1259-68. PubMed PMID: 10950117.
  17. Vaarala MH, Porvari KS, Kyllönen AP, Mustonen MV, Lukkarinen O, Vihko PT. Several genes encoding ribosomal proteins are over-expressed in prostate-cancer cell lines: confirmation of L7a and L37 over-expression in prostate-cancer tissue samples. Int J Cancer. 1998 Sep 25;78(1):27-32. PubMed PMID: 9724090.
  18. Leskinen MJ, Mehik A, Sarpola A, Tammela TL, Järvelin MR. The Finnish version of The National Institutes Of Health Chronic Prostatitis Symptom Index correlates well with the visual pain scale: translation and results of a modified linguistic validation study. BJU Int. 2003 Aug;92(3):251-6. PubMed PMID: 12887478.
  19. Mehik A, Hellström P, Nickel JC, Kilponen A, Leskinen M, Sarpola A, Lukkarinen O. The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol. 2002 Jan;167(1):137-40. PubMed PMID: 11743292.
  20. Mehik A, Hellström P, Sarpola A, Lukkarinen O, Järvelin MR. Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. BJU Int. 2001 Jul;88(1):35-8. PubMed PMID: 11446842.

Supervised doctoral dissertations:

  1. Ronkainen, Hanna-Leena: Novel prognostic biomarkers for renal cell carcinoma. 2012

Last updated: 13.11.2018